Mid-Year CDMO Review: COVID-19 Vaccine Manufacturing and M&A

DCAT Value Chain Insights’ Production to Prescription

Chapters
1:27
CDMOs and COVID-19 vaccine manufacturing
5:28
Potential implications of increased injectables capacity
8:12
CDMO M&A remains robust
10:49
Cell and gene therapies: a major source of CDMO M&A
11:35
Private equity and CDMO M&A
13:14
Largest deal thus far: Thermo Fisher Scientific/PPD
DCAT Value Chain Insights’ Production to Prescription
Mid-Year CDMO Review: COVID-19 Vaccine Manufacturing and M&A
Jun 11, 2021
DCAT

What have been the key developments in 2021 thus far in the CDMO market? In this podcast we take a look at the increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity that have marked the first half of 2021. What are the implications, and what can be expected going forward? For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

  • CDMOs and COVID-19 vaccine manufacturing
  • Potential implications of increased injectables capacity
  • CDMO M&A remains robust
  • Cell and gene therapies: a major source of CDMO M&A
  • Private equity and CDMO M&A
  • Largest deal thus far: Thermo Fisher Scientific/PPD

Sponsor: Vetter Pharma International GmbH

Links:

Subscribe to our e-newsletter at www.dcatvci.org

Follow us on Twitter @DCATvci

Support the show (https://dcat.org/MemberApplication.htm)

Support the show